Estrogenic activity of a polyphenolic extract of the leaves of Epimedium brevicornum

Ghent University, Faculty of Pharmaceutical Sciences, Laboratory of Pharmacognosy and Phytochemistry, Harelbekestraat 72, B-9000 Ghent, Belgium.
Fitoterapia (Impact Factor: 2.22). 02/2005; 76(1):35-40. DOI: 10.1016/j.fitote.2004.10.002
Source: PubMed

ABSTRACT The estrogenic activity of a polyphenolic extract of the leaves of Epimedium brevicornum and five fractions obtained by solid-phase extraction were investigated using estrogen-responsive bioassays, a yeast cell assay and the Ishikawa Var-I assay. The extract was found to exhibit significant estrogenic activity in both assays. Furthermore, bioassay-guided fractionation led to localisation of the estrogenicity in the relatively non-polar fractions of the polyphenolic extract.


Available from: Stuart R Milligan, Jun 02, 2015
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study characterizes the correlation between the chemical fingerprint and estrogenic activity of an Epimedium koreanum extract. The estrogenic activity of 31 E. koreanum extract samples was evaluated by a luciferase reporter gene assay, and the samples were classified into 3 groups based on their bioactivity. A chemical fingerprint analysis was performed on each sample by high-performance liquid chromatography (HPLC), and 44 common peaks were selected from the chromatogram and used as a dataset for a pattern recognition analysis. A canonical discriminant analysis performed on this dataset determined a distinct distribution of the samples according to their estrogenic activity on the scoring plot. The classification results showed that 90.3% of the original grouped cases had been correctly classified. The total content of the 4 major extract compounds, epimedin A, epimedin B, epimedin C, and icariin, exhibited good correlation (r=0.784) with the estrogenic activities of the respective extracts. This chromatographic fingerprint-chemometric analysis system could be useful for predicting the E. koreanum pharmacological activity and consequent biological activity-relevant quality control assessment.
    Bioscience Biotechnology and Biochemistry 05/2012; 76(5):923-7. DOI:10.1271/bbb.110922 · 1.21 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Er-Xian Decoction (EXD), Epimedium herbs (herbs of Epimedium brevicornum Maxim, EBH), and icariin (ICA) have been proven to have estrogen-like and antiosteoporotic activity and are used for the treatment of osteoporosis, menopausal syndrome, and age-associated diseases. The present study found that EXD, EBH, and ICA treatments, emulating estrogen, significantly contributed to bone density and architecture in OVX rats and that EXD is similar to estrogen and exerts a concomitant effect on bone formation and bone resorption at the tissue level, while EBH and ICA produced bone-protective effects mainly by inhibiting bone resorption. Nevertheless, EXD, EBH, and ICA treatments manifested a fewer adverse effects on the uterus, mammary gland, and vagina compared to estrogen administrations. Among the EXD, EBH, and ICA, EXD was found to have superior efficacy and safety profile.
    Evidence-based Complementary and Alternative Medicine 11/2012; 2012:241416. DOI:10.1155/2012/241416 · 2.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this work, the metabolite profiles of epimedin B in rat feces, bile, urine and plasma were qualitatively investigated, and the possible metabolic pathways of epimedin B were subsequently proposed. After oral administration of epimedin B at a single dose of 80 mg/kg, rat biological samples were collected and pretreated by protein precipitation. Then these pretreated samples were injected into an Acquity UPLC BEH C18 column with mobile phase consisted of 0.1% formic acid water and 0.1% formic acid acetonitrile and detected by Ultra-performance Liquid Chromatography/quadrupole-time-of-flight Mass Spectrometry (UPLC-Q-TOF/MS). In all, 43 metabolites were identified in the biosamples. Of these, 13, including F5, F7, F16-F17, F18, D5, D6, D7, D9, N5, N7, M1 and M3, were, to our knowledge, reported for the first time. The results indicated that epimedin B was metabolized via desugarization, dehydrogenation, hydrogenation, hydroxylation, demethylation, glucuronidation and glycosylation pathways in vivo. Specific hydrolysis of 7-O glucosides in the gut lumen and glucuronic acid conjugation in liver were considered as the main physiologic processes of epimedin B. This study revealed the possible metabolite profiles of epimedin B in rats.
    Journal of Agricultural and Food Chemistry 01/2013; 61(15). DOI:10.1021/jf304625x · 3.11 Impact Factor